April 1, 2014
/PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that data from the Company's SparVax
next-generation anthrax vaccine program were recently presented at the
8 th Annual New Technologies, New Vaccines
conference. In a presentation entitled,
"Factors that Affect Potency and Stability for a Recombinant Protective Antigen Vaccine,"
, Director, Analytical Sciences at PharmAthene, presented results demonstrating the Company's achievements in developing key analytical assays which are being employed to monitor the stability and potency of SparVax
"We believe SparVax
is a promising alternative to the current anthrax vaccine and other rPA-based vaccines due, in part, to its unique formulation. This formulation, and our development of newer, more precise assays have facilitated the development and testing of a vaccine product with enhanced stability and potency," said Dr. Powell. "Further, our research has demonstrated that subtle changes in the interaction between rPA and an immune-stimulating adjuvant (Alhydrogel
) yield important improvements in stability and immunogenicity."
Data presented by Dr. Powell show how the addition of phosphate alters the surface chemistry of the immune-stimulating adjuvant, Alhydrogel
in such a way that the stability profile of rPA is improved and potency is increased, as compared to vaccine formulations with less phosphate. In addition, the phosphate/Alhydrogel
formulation demonstrated five-fold higher potency than a comparable low phosphate formulation, as tested in the prior mouse challenge assay.
The need for newer anthrax vaccines based on modern vaccine technology, which offer the potential for improved safety, convenience and cost-effectiveness, is widely acknowledged. SparVax
is a next-generation anthrax vaccine being developed for pre- and post-exposure protection against anthrax. It is based on recombinant protective antigen (rPA), the principal virulence factor of the bacterial organism,
B. anthracis (anthrax).
PharmAthene's rPA anthrax vaccine program has been supported by funding from the National Institute of Allergy and Infectious Disease, National Institutes of Health, and the Biomedical Advanced Research and Development Authority.